Clinical Trial Detail

NCT ID NCT02558348
Title Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
Recruitment Terminated
Gender female
Phase Phase Ib/II
Variant Requirements yes
Sponsors Advenchen Laboratories, LLC
Indications

fallopian tube cancer

peritoneum cancer

endometrial carcinoma

ovarian cancer

cervical squamous cell carcinoma

Therapies

Anlotinib

Age Groups: adult senior

Additional content available in CKB BOOST